RCM
SLXNW

Rivernorth Capital Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Rivernorth Capital Management’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,999
Closed -$1.15K – 385
2025
Q1 		$1.15K Hold
14,999
– – ﹤0.01% 344
2024
Q4 		$508 Hold
14,999
– – ﹤0.01% 401
2024
Q3 		$472 Buy
+14,999
New +$868 ﹤0.01% 375

Other funds holding SLXNW

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Rivernorth Capital Management's SLXNW Position: Q2 2025 in Review

Rivernorth Capital Management sold out of Silexion Therapeutics Warrant (SLXNW) in Q2 2025, closing a stake of 14,999 shares — an estimated $1.15K sold.

Rivernorth Capital Management first reported a position in SLXNW in Q3 2024 and held it in 3 quarters. The position peaked at $1.15K in Q1 2025. 22 funds tracked by Wall St. Rank hold SLXNW as of Q2 2025.

  • Rivernorth Capital Management reported no remaining Silexion Therapeutics Warrant position as of Q2 2025 after selling out during the quarter.
  • Rivernorth Capital Management sold 14,999 Silexion Therapeutics Warrant shares in Q2 2025, an estimated $1.15K.
  • Rivernorth Capital Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 3 quarters.
  • Rivernorth Capital Management's Silexion Therapeutics Warrant position peaked at $1.15K in Q1 2025.
  • 22 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2025.

Based on Rivernorth Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.